Overview |
bs-13058R |
EEF2k (Ser359) Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Human, Mouse, Rat, Dog, Sheep, Horse, Chicken, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human EEF2k around the phosphorylation site of Ser359 |
Ser359 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
29904 |
Cytoplasm |
EEF2K phospho S359; p-EEF2K phospho S359; Calcium/calmodulin dependent eukaryotic elongation factor 2; Calcium/calmodulin dependent eukaryotic elongation factor 2 kinase; Calmodulin dependent protein kinase III; cb365; eEF 2 kinase; eEF 2K; EEF2K protein; Elongation factor 2 kinase; Eukaryotic elongation factor 2 kinase; kinase eEF2K; SMEF2K; EF2K_HUMAN. |
Eukaryotic elongation factor 2 kinase (EEF2k) previously known as Ca2+/calmodulin dependent protein kinase III, is an abundant cytoplasmic protein highly specific for elongation factor 2 (eEf2). Phosphorylation of eEF2 by eEF2 kinase on specific threonine residues results in the inactivation of eEF-2 and in termination of mRNA translation. The activity of eEF2 kinase is not only dependent upon Ca2+ ions, calmodulin (CaM) and insulin, but is also regulated both negatively and positively via phosphorylation by different protein kinases (AMPK, S6K1, p90 RSK). There is also evidence that eEF-2 phosphorylation is involved in the regulation of cell cycle progression, cellular differentiation, oogensis and malignant tumors. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |